Email Sign-Up
 
8 results found
Filter Filters icon
Apply

Story 12/19/22

Ibrance adds no benefit over Faslodex alone

Participants with HR-positive metastatic breast cancer saw no benefit from adding the CDK inhibitor but a small group who also got immunotherapy had a longer period without disease growth

Article

Types of immunotherapy

Learn more about the types of immunotherapy and some breast cancer medicines within each class.

Article

Atezolizumab

Atezolizumab (Tecentriq) is an immunotherapy that was granted accelerated approval by the Food and Drug Administration in March 2019 to treat metastatic triple-negative breast cancer that ...

Article

Pembrolizumab

Pembrolizumab (Keytruda) is an FDA approved immunotherapy medicine that uses the body’s own immune system to attack cancer cells in some metastatic or triple-negative breast cancers and ...

Article

Immunotherapy

Immunotherapy is the use of medicines to help the body’s own immune system recognize and destroy cancer cells. It is a type of biological therapy, which is a class of treatments that use ...

Story 12/08/21

Immunotherapy drug offers effective new treatment for triple-negative breast cancer

The first day of the 2021 San Antonio Breast Cancer Symposium (SABCS) included findings from two clinical trials that show the immunotherapy drug pembrolizumab (Keytruda) offers a new treatment ...

Story 08/09/21

Pembrolizumab approved for high-risk triple-negative breast cancer

The FDA approved the use of pembrolizumab (Keytruda) to treat some early-stage, triple-negative breast cancers, marking the first time an immunotherapy medicine has been approved for use in ...

Story 12/13/19

Pembrolizumab benefits common across subgroups in early-stage, triple-negative breast cancer

Updates from a recent study show improvements in pathological complete response affect women with different personal and tumor features.